NCT03398421 - A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

March 12, 2018

Study Completion Date

March 12, 2018

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Nemiralisib

Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.

DRUG

Itraconazole

Itraconazole will be given as 100 mg per capsule per day administered orally with water

Trial Locations (1)

66211

GSK Investigational Site, Overland Park